Repligen | RGEN - Capital Ordinário





Capital Ordinário Alterar Data
Agilent USD 282.22M 478K 2026-03
Align Technology USD 71.62M 133K 2026-03
Bio Techne USD 156.45M 703K 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Bruker USD 152.22M 282K 2026-03
Charles River Laboratories USD 48.17M 1.05M 2026-03
Danaher USD 702.9M 4.8M 2026-06
Dentsply International USD 200.3M 700K 2026-03
General Electric Aerospace USD 1.04B 5.77M 2026-06
Henry Schein USD 114.42M 1.35M 2026-03
Illumina USD 151.91M 893K 2026-03
IQVIA Holdings USD 166.9M 2.7M 2026-03
Mettler Toledo International USD 20.25M 179.94K 2026-03
Myriad Genetics USD 93.5M 400K 2025-12
OraSure Technologies USD 70.39M 1.87M 2025-12
Pacific Biosciences Of California USD 301.96M 103K 2025-12
Pfizer USD 5.7B 13M 2026-03
Repligen USD 56.4M 74K 2026-03
Revvity USD 111.8M 1.57M 2026-03
Standard Biotools USD 390.14M 3.76M 2026-03
Thermo Fisher Scientific USD 371.62M 4.09M 2026-03
Waters USD 98.17M 89K 2026-03
West Pharmaceutical Services USD 70.9M 1.1M 2026-03